Novel cellular factor-containing solution compositions
AssigneeStemnion, Inc.
InventorsVivienne S. Marshall, Charlotte A. Smith, Catherine J. Trumpower, George L. Sing, Linda O. Palladino
Life of this patent
Estimating the term…
Abstract
The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.
Claims24
An extraembryonic cell-derived cellular cytokine solution composition comprising physiologic concentrations of:
- a) at least one factor selected from VEGF, TGFβ2, Angiogenin and PDGF;
- and
- b) at least one MMP inhibitor.
A method of making an amnion-derived cellular cytokine solution comprising
- a) isolating amnion epithelial cells from the amnion of a placenta,
- b) selecting AMP cells from the amnion epithelial cells,
- c) culturing the AMP cells until they reach confluence,
- d) changing the culture medium,
- e) culturing the cells in the medium, and
- f) collecting the culture medium of step (e) to obtain amnion-derived cellular cytokine solution.
A physiologic cytokine solution composition comprising a therapeutic component consisting essentially of physiologic concentrations of:
- a) one or more factors selected from VEGF, TGFβ2, Angiogenin and PDGF;
- b) at least one MMP inhibitor;
- and
- c) a carrier, wherein the physiologic concentration is ˜5.0-16 ng/mL for VEGF, ng/mL for Angiogenin, ˜100-165 pg/mL for PDGF, ˜2.5-2.7 ng/mL for TGFβ2, ˜0.68 μg mL for TIMP-1 and ˜1.04 μg/mL for TIMP-2, and wherein the carrier is normal saline, PBS, lactated Ringer's solution or cell culture medium.
A physiologic cytokine solution composition comprising a therapeutic component consisting essentially of a composition selected from the group consisting of:
- Composition A:
- VEGF and TIMP-1;
- Composition B:
- VEGF, Angiogenin and TIMP-1;
- Composition C:
- VEGF, Angiogenin, PDGF-BB and TIMP-1;
- Composition D:
- VEGF, Angiogenin, PDGF-BB, TGFβ2 and TIMP-1;
- Composition E:
- VEGF and TIMP-2;
- Composition F:
- VEGF, Angiogenin and TIMP-2;
- Composition G:
- VEGF, Angiogenin, PDGF-BB and TIMP-2;
- Composition H:
- VEGF, Angiogenin, PDGF-BB, TGFβ2 and TIMP-2;
- Composition I:
- VEGF, TIMP-1 and TIMP-2;
- Composition J:
- VEGF, Angiogenin, TIMP-1 and TIMP-2;
- Composition K:
- VEGF, Angiogenin, PDGF-BB, TIMP-1 and TIMP-2;
- Composition L:
- VEGF, Angiogenin, PDGF-BB, TGFβ2, TIMP-1 and TIMP-2;
- Composition M:
- Angiogenin and TIMP-1;
- Composition N:
- Angiogenin, PDGF-BB and TIMP-1;
- Composition O:
- Angiogenin, PDGF-BB, TGFβ2 and TIMP-1;
- Composition P:
- Angiogenin and TIMP-2;
- Composition Q:
- Angiogenin, PDGF-BB and TIMP-2;
- Composition R:
- Angiogenin, PDGF-BB, TGFβ2 and TIMP-2;
- Composition S:
- Angiogenin, PDGF-BB, TGFβ2, TIMP-1 and TIMP-2;
- Composition T:
- PDGF-BB and TIMP-1;
- Composition U:
- PDGF-BB, TGFβ2 and TIMP-1;
- Composition V:
- PDGF-BB and TIMP-2;
- Composition W:
- PDGF-BB, TGFβ2 and TIMP-2;
- Composition X:
- PDGF-BB, TIMP-1 and TIMP-2;
- and Composition Y:
- PDGF-BB, TGFβ2, TIMP-1 and TIMP-2;
- and a carrier, wherein VEGF, Angiogenin, PDGF-BB, TGFβ2, TIMP-1 and TIMP-2 are at ˜5-16 ng/mL for VEGF, ˜3.5-4.5 ng/mL for Angiogenin, ˜100-165 pg/mL for PDGF, ˜2.5-2.7 ng/mL for TGFβ2, ˜0.68 μg mL for TIMP-1 and ˜1.04 μg/mL for TIMP-2, and wherein the carrier is normal saline, PBS, lactated Ringer's solution or cell culture medium.
A method of making a sustained-release composition comprising the steps of combining a cellular factor-containing solution composition with an agent capable of effecting sustained-release of the cellular factor-containing solution composition.
Dependencies are inferred from the claim text.